Evidence map›Paper›PMID 33809415›Full record

ArticleVaccines2021

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies.

Pedro M Folegatti, Amy Flaxman, Daniel Jenkin, Rebecca Makinson, Lucy Kingham-Page, Duncan Bellamy, Fernando Ramos Lopez, Jonathan Sheridan, Ian Poulton, Jeremy Aboagye and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Developing the next-generation of adenoviral vector vaccines.Human vaccines & immunotherapeutics · 2025
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Pedro M FolegattiThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0001-5330-0240
Amy FlaxmanThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0001-6460-1372
Daniel JenkinThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0003-3088-310X
Rebecca MakinsonThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Lucy Kingham-PageThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0001-7891-6359
Duncan BellamyThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0003-3614-0032
Fernando Ramos LopezThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0002-9997-7879
Jonathan SheridanThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0002-6806-2609
Ian PoultonThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Jeremy AboagyeThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Nguyen TranThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Celia MittonThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Rachel RobertsThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Alison M LawrieThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Adrian V S HillThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0003-0900-9629
Katie J EwerThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0001-9827-9836
Sarah GilbertThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0002-6823-9750

Funding

HAV Vaccines Ltd HAV001
6 · The paper itself

Abstract

Heterologous prime-boost strategies are known to substantially increase immune responses in viral vectored vaccines. Here we report on safety and immunogenicity of the poxvirus Modified Vaccinia Ankara (MVA) vectored vaccine expressing four Mycobacterium avium subspecies paratuberculosis antigens as a single dose or as a booster vaccine following a simian adenovirus (ChAdOx2) prime. We demonstrate that a heterologous prime-boost schedule is well tolerated and induced T-cell immune responses.

Indexed as

T-Cellvaccineviral vector

Identifiers

PMID33809415
PMCPMC8000717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.